Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Keep Calm, Bear Markets Are Temporary

We may very well be headed for a recession—some economists believe it’s already here —but we’re most definitely in a bear market, normally defined as occurring when stocks are off more than 20 percent from their peak. Not only that, bu...

Pandemic fears: real and imagined

“Pandemic”. Few words in the English language conjure as much fear. The mere utterance evokes images of dying patients, surgical masks, haz-mat suits, a parade of coffins, helpless doctors and nurses, as the contagion spreads, first striking down the el...

The Right Tools at the Right Time to Control Crop Disease & Boost Yields

Download the episode here . Agri-tech Company Bee Vectoring Technologies International Inc. ( TSX-V: BEE , OTCQB: BEVVF , Forum ) has pioneered a unique and natural precision agriculture system that uses commercially-grown bees to deliver biological crop ...

Alzheimer’s Breakthrough: Why the Experts are Betting on NervGen

It's the disease that most of us regard with the greatest dread – especially since nearly one in every three people will eventually be afflicted. This is why a breakthrough pharmaceutical drug for Alzheimer’s disease would not only be a godsend to society,...

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 m...

Buzz on the Bullboards: T’is the Season for a Rebound?

(Image via SweetWater Brewing Co.) It happens every year, the mood among North American markets changes drastically once American Thanksgiving passes and despite a “socially distanced” holiday this year, that still holds true. Traders are ...

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. Neurodegen...

Living in a virus-controlled world

As the coronavirus pandemic continues to infect populations, though in some countries it is slowing, talk has shifted to re-opening economies, and to manufacturing a vaccine that drug companies hope will not only work, but can be distributed at large enough doses to provide ...

Copper price's fall from 2022 highs might only be temporary

The copper story has had its ups and downs. Currently it’s trading at around US$3.80. Copper’s high point came in March 2022 at US$5.02 a pound. With optimism on higher prices at the start of the year, expectations have not been met as Chi...

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...
1 2 3 4 5 6 7 8 9 10 ...